Evidence map›Paper›PMID 37239929›Full record

ArticleInternational journal of molecular sciences2023

Exploring BenzylethoxyAryl Urea Scaffolds for Multitarget Immunomodulation Therapies.

Raquel Gil-Edo, German Hernández-Ribelles, Santiago Royo, Natasha Thawait, Alan Serrels, Miguel Carda, Eva Falomir

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.3field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Raquel Gil-EdoInorganic and Organic Chemistry Department, University Jaume I, 12071 Castellón, Spain.ORCID 0000-0002-2977-7783
German Hernández-RibellesCurapath, Benjamin Franklin Avenue 19, 46980 Paterna, Spain.
Santiago RoyoInstitute of Agronomic Engineering for Development, Polytechnic University of Valencia, 46022 Valencia, Spain.ORCID 0000-0001-9570-7081
Natasha ThawaitCancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK.ORCID 0000-0002-8321-3292
Alan SerrelsCancer Research UK Scotland Centre, Institute of Genetics and Cancer, University of Edinburgh, Crewe Road South, Edinburgh EH4 2XR, UK.
Miguel CardaInorganic and Organic Chemistry Department, University Jaume I, 12071 Castellón, Spain.
Eva FalomirInorganic and Organic Chemistry Department, University Jaume I, 12071 Castellón, Spain.ORCID 0000-0003-0329-6313
Universitat Jaume I · ESEdinburgh Cancer Research · GBUniversitat Politècnica de València · ES

Funding

Asociación Española Contra el Cáncer PRDCA18002CARDCancer Research UK 25919Jaume I University UJI-B2021-46Ministerio de ciencia e innovación PID2021-1267770B-100Ministerio de Economía y competividad RTI2018-097345-B-I00
6 · The paper itself

Abstract

Thirteen benzylethoxyaryl ureas have been synthesized and biologically evaluated as multitarget inhibitors of VEGFR-2 and PD-L1 proteins to overcome resistance phenomena offered by cancer. The antiproliferative activity of these molecules on several tumor cell lines (HT-29 and A549), on the endothelial cell line HMEC-1, on immune cells (Jurkat T) and on the non-tumor cell line HEK-293 has been determined. Selective indexes (SI) have been also determined and compounds bearing

Indexed as

NeoplasmsUreaCell Line, TumorCell ProliferationHEK293 CellsHumansImmunomodulationUreaangiogenesisaryl ureabenzylethoxyaryl ureaCD11bCD69CD8+ T cellFynimmune checkpointsLAG-3LATLCKOX-40PD-1PD-L1TIM-3TLCRsVEGFR-2ZAP70

Identifiers

PMID37239929
PMCPMC10218498
OpenAlexW4376138187

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.